GET DAILY SIGNALSMilestone Scientific (MLSS) Q3 Update: Tracking Medical Momentum and Cash Runway
Key Takeaways
- Milestone Scientific Inc. (NYSE: MLSS) is scheduled to report results for its third quarter ended September 30, 2026, before the market opens on Friday, November 13, 2026, followed by a conference call at 8:30 AM Eastern Time.
- Management has guided third-quarter revenue to roughly $2.3 million to $2.5 million, a sequential step down from $2.8 million in the second quarter, reflecting the absence of two large non-recurring international dental orders and typical seasonal softness.
- Full-year 2026 revenue guidance remains $9.8 million to $10.2 million, implying double-digit growth, with analysts tracking earnings per share (EPS) near breakeven at about a $0.01 net loss.
- Investors will focus on the CompuFlo medical segment's momentum, recent Medicare reimbursement expansion, and the new Red One Medical federal distribution agreement.
- The company's cash position remains thin at roughly $2.1 million as of June 30, 2026, with management targeting cash flow breakeven in early 2027.
Why This Quarter Matters
Milestone Scientific develops computer-controlled drug delivery instruments that enable precise, painless injections through its Dynamic Pressure Sensing (DPS) technology. The company sits at an interesting point where its established dental business offers stability while the CompuFlo medical platform, used for epidural procedures, serves as the primary growth engine. The third-quarter report will show whether early medical adoption and expanded Medicare reimbursement can offset the seasonal slowdown in dental sales that management has already highlighted. With limited cash on hand and a target of reaching cash flow breakeven in early 2027, this update provides a useful check on operating leverage, cost control, and the sustainability of the double-digit growth path.
Revenue and Earnings Expectations
For the quarter ended September 30, 2026, management expects revenue in the $2.3 million to $2.5 million range, down from $2.8 million in the second quarter. This sequential drop stems from the lack of repeat large international dental orders and normal summer seasonality. Consensus points to revenue around $2.4 million, essentially flat to slightly higher year over year, with a net loss near $0.01 per share. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Key metrics to watch include gross margin, which fell to 67.2% in the second quarter due to product mix and tariff pressures, operating expense management that has helped reduce losses, and medical segment growth that rose 231% year over year in the second quarter from a small base. Full-year guidance stays at $9.8 million to $10.2 million, and any updates on Medicare Administrative Contractor reimbursement progress or the Red One Medical federal distribution rollout will draw attention.
Investor Sentiment and Potential Market Reaction
Heading into the report, sentiment appears measured given the company's modest size, limited cash reserves, and still-developing medical business. Shares have reacted to prior releases, declining after the first-quarter results and falling roughly 10% after the second quarter even with 22% year-over-year revenue growth. Main risks include the expected sequential revenue dip, continued gross-margin pressure from tariffs and mix, and questions around turning Medicare reimbursement and federal distribution deals into steady medical sales. The focus will be on whether cost reductions keep narrowing losses and whether second-half growth drivers remain on track.
Looking Forward After the Print
After the third-quarter numbers, attention will turn to whether Milestone Scientific can deliver the stronger second half implied by its full-year guidance. Medical initiatives, including expanded Medicare and commercial payer channels, are expected to add more in the back half of 2026. The Red One Medical agreement opens doors to federal systems such as the Department of Veterans Affairs, Department of Defense, and Indian Health Service, though first orders were slated for the fourth quarter and carry no minimum commitments. Medicare reimbursement expansion across additional regions is another item to follow. Cash and liquidity will also stay in view, with $2.1 million on hand as of June 30, 2026, making disciplined spending and revenue growth essential for the early-2027 breakeven target.
AI Tools in My Analysis Workflow
When evaluating smaller healthcare names like this one, I often turn to Tickeron’s AI Screener to quickly compare technical patterns, fundamentals, and sector momentum across similar companies. It helps surface relevant trade ideas and track how shifting reimbursement or distribution trends might affect peers without spending hours on manual screens.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MLSS's RSI Indicator ascending out of oversold territory
The RSI Oscillator for MLSS moved out of oversold territory on October 28, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 25 similar instances when the indicator left oversold territory. In 22 of the 25 cases the stock moved higher. This puts the odds of a move higher at 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for MLSS just turned positive on October 29, 2026. Looking at past instances where MLSS's MACD turned positive, the stock continued to rise in 36 of 46 cases over the following month. The odds of a continued upward trend are 78%.
Following a +3.55% 3-day Advance, the price is estimated to grow further. Considering data from situations where MLSS advanced for three days, in 179 of 229 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MLSS as a result. In 97 of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MLSS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for MLSS entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 75 (best 1 - 100 worst), indicating slightly worse than average price growth. MLSS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.884) is normal, around the industry mean (4.964). P/E Ratio (-6.040) is within average values for comparable stocks, (40.591). MLSS's Projected Growth (PEG Ratio) (37.320) is very high in comparison to the industry average of (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (3.601) is also within normal values, averaging (56.876).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MLSS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of subcutaneous injection technology for dental and medical applications
Industry PharmaceuticalsOther
Advertisement